Inspiremd appoints leading interventional cardiologist chris metzger, m.d. as principal investigator for cguard registration trial in the united states

Tel aviv, israel, feb. 09, 2021 (globe newswire) -- inspiremd, inc. (nyse american: nspr), developer of the cguard™ embolic prevention system (eps) for the prevention of stroke caused by carotid artery disease, announced today the appointment of chris metzger, m.d., system chair of clinical research at ballad health system in eastern tennessee as the principal investigator for its planned fda registration trial for cguard eps.
NSPR Ratings Summary
NSPR Quant Ranking